LitAlert ~~ GeneLit.com

    • Niraparib treatment for patients with BRCA-mutated ovarian cancer: review of clinical data and therapeutic context.
    • González-Martín A, Matulonis UA, Korach J, Mirza MR, Moore KN, Wu X, York W, Gupta D, Lechpammer S, Monk BJ.
    • Future Oncol. 2022 Jul 6. doi: 10.2217/fon-2022-0206. Epub ahead of print.
    • Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary.
    • Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C.
    • Gynecol Oncol. 2022 Jul 5:S0090-8258(22)00421-8. doi: 10.1016/j.ygyno.2022.06.017. Epub ahead of print.
    • Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
    • Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, Reeves J, Pan P, Shan M, Tang Y, Graham JR, Hazard S, Ellisen LW, Isakoff SJ.
    • Nat Cancer. 2022 Jul 4. doi: 10.1038/s43018-022-00400-2. Epub ahead of print.

    Identifier: NCT03329937: Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Participants With Breast Cancer. (ClinicalTrials.gov)

    • The impact of rare germline variants on human somatic mutation processes.
    • Vali-Pour M, Lehner B, Supek F.
    • Nat Commun. 2022 Jun 28;13(1):3724. doi: 10.1038/s41467-022-31483-1.

    Research news: Cancer Risk May Be Influenced by Rare Germline Variants. (Inside Precision Medicine)

    • Ethical, legal, and sociocultural challenges of genomic research in Jordan: a mixed methods study in patients with breast cancer with Jordanian-Palestinian heritage.
    • Al-Omari A, Al-Hussaini M, Zahran F, Abdel-Razeq H.
    • Lancet. 2022 Jun;399 Suppl 1:S26. doi: 10.1016/S0140-6736(22)01161-8.